Teva's Macitentan Approval Signals Increased Competition in Pulmonary Arterial Hypertension
Cardiology · Pulmonary Arterial Hypertension • Regulatory Approval • Jun 23, 2026
Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
Executive Thesis
The FDA's approval of Teva's ANDA for Macitentan introduces a new competitor in the pulmonary arterial hypertension market, which could disrupt pricing and market share for existing therapies. Pharma strategy teams must evaluate the implications for their portfolios and adjust strategies accordingly. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 13 ranked evidence items (5 high-relevance).
Strategic Assessment
Portfolio teams should assess the impact of Teva's entry on market dynamics and pricing strategies for similar products. The strongest clinical anchor is Pulmonary Hypertension (PH) Biorepository for Translational Research (ClinicalTrials.gov), sub-indication match (cardiology). In cardiology, 6 regulatory and 1 competitive items passed relevance filtering for Teva.
Competitive Pressure
The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). This approval allows Teva to enter the market for Macitentan, potentially increasing competition against existing therapies for pulmonary arterial hypertension.
Regulatory Outlook
Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). While the approval itself is a positive regulatory development for Teva, it may prompt increased scrutiny and regulatory considerations for existing therapies in response to heightened competition.
Key Risks
- Elevated medium regulatory exposure for Teva could delay market entry or constrain labeling if agency review intensifies.
- Signal severity is high — leadership review is warranted.
- Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Teva through agency review timelines and labeling constraints if follow-through weakens.
Key Opportunities
- Teva's entry into the market could significantly affect revenue streams and market positioning for current players in the pulmonary arterial hypertension space, necessitating strategic pricing and marketing adjustments.
- Upside for Teva may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
- Portfolio teams should assess the impact of Teva's entry on market dynamics and pricing strategies for similar products.
What Would Change This Assessment
- This becomes more urgent if Monitor market uptake of Teva's Macitentan and any competitive responses from other manufacturers.
- Additional medium- or high-relevance evidence would materially upgrade this assessment.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View sourceFDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — MACITENTAN (ORIG)
FDAmedium relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — MACITENTAN (ORIG)
FDAmedium relevance
Entity match (macitentan); Regulatory pathway relevance (nda)
FDA document
View source
Pulmonary Hypertension (PH) Biorepository for Translational Research
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View sourcePulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View sourceDevelopment of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View sourceEffectiveness of Digital Health Application for Primary Hypertension (Liebria)
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View sourceCognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View sourceFDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient
Mercklow relevance
Sponsor/company relevance (Merck)
FDA document
View source
Electroacupuncture for essential hypertension: Mechanistic insights, current clinical evidence, and translational challenges.
PubMedhigh relevance
Sub-indication match (cardiology)
FDA document
View sourceSafety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedhigh relevance
Sub-indication match (cardiology)
FDA document
View sourceImmune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Related Signals
- FDA Grants Approval for Macitentan ANDA211187 by Teva Pharmaceuticals
Regulatory Approval
Related Regulatory Precedents
FDA
Withdrawn | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.
SourceFDA
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
SourceMHRA
Clinical trials for medicines: modifying a clinical trial approval
Guidance on the various types of modifications that can be made to a clinical trial approval.
SourceFDA
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
SourceFDA
FDA AP — MACITENTAN (ORIG)
Application ANDA211000. Sponsor: AMNEAL. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: MACITENTAN.
Source